Investing Ideas
/
Swiss Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals

Swiss Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

0 new

High return on equity, past performance and sound balance sheet.

1 companies

Basilea Pharmaceutica

Market Cap: CHF 657.4m

A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.

BSLN

CHF 53.50

0.2%

29.4%